Merck Tbk PT

Merck Tbk PT FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Merck Tbk PT (MERK.JK) as of Oct 17, 2026 is 147.97 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 25.34 % — a change of 484.06% (higher).

FCF Conversion

147.97 %

YoY

484.06%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Merck Tbk PT is 2025 147.97 % . FCF Conversion Rate (FCF/EBITDA) of Merck Tbk PT was 2024 25.34 % . It decreases by 484.06% higher compared to the previous year.

The Merck Tbk PT FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
12.47 IDR
Jan 1, 2019
-307.63 IDR
Jan 1, 2020
56.41 IDR
Jan 1, 2021
96.25 IDR
Jan 1, 2022
50.12 IDR
Jan 1, 2023
103.22 IDR
Jan 1, 2024
25.34 IDR
Jan 1, 2025
147.97 IDR
The Merck Tbk PT FCF Conversion history
YEARFCF ConversionYoY
147.97 %+484.06%
25.34 %-75.45%
103.22 %+105.93%
50.12 %-47.92%
96.25 %+70.63%
56.41 %-118.34%
-307.63 %-2,566.38%
12.47 %-71.97%
44.50 %+273.87%
11.90 %-83.29%
71.24 %-38.27%
115.40 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Merck Tbk PT Stock analysis

What does Merck Tbk PT do? Merck Tbk PT is a pharmaceutical company based in Jakarta Timur, DKI Jakarta, operating within the Health Care sector. The company, listed on the Indonesian stock exchange with ticker MERK.JK and ISIN ID1000136609, has been publicly traded since its IPO on July 23, 1981. It employs 376 full-time staff and focuses on the development and distribution of pharmaceutical and chemical products. The company operates through three business segments: Biopharma, which covers ethical pharmaceutical products; Consumer Health, which includes over-the-counter products; and Others, which encompasses additional business activities. Merck Tbk PT is committed to providing personalized treatments for serious diseases and supports initiatives related to reproductive health, including enabling individuals to achieve their goal of becoming parents. The company's official website is https://www.merckgroup.com/id-id, where further information about its operations and services can be accessed. As a publicly listed entity, Merck Tbk PT is subject to regulatory disclosures and financial reporting requirements in Indonesia. The company's primary focus remains on delivering healthcare solutions through its pharmaceutical and chemical offerings, targeting both professional medical markets and consumer health needs. Merck Tbk PT is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Merck Tbk PT stock

FCF Conversion Rate (FCF/EBITDA) of Merck Tbk PT is 147.97 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Merck Tbk PT changed from 25.34 % to 147.97 %, representing a 484.06% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Merck Tbk PT since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Merck Tbk PT with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Merck Tbk PT

All Key Metrics — Merck Tbk PT